Please login to the form below

Santaris

This page shows the latest Santaris news and features for those working in and with pharma, biotech and healthcare.

Roche boosts respiratory presence with InterMune purchase

These include a $450m deal to acquire gene silencing specialist Santaris earlier this month, an offering of $1.7bn for cancer company Seragon in July and a $350m bargain for sequencing

Latest news

Chugai soars on Roche buyout rumours

Roche has been making targeted acquisitions of late – offering $450m for gene silencing company Santaris earlier this month, $1.7bn for cancer company Seragon Pharmaceuticals in July and $350m for sequencing
Roche pays $450m for 'gene-silencing' firm Santaris Pharma

Roche's return to the field of RNAi research looks to be complete, following its $450m deal to acquire Denmark's Santaris Pharma. ... The deal is expected to close later this month, when Santaris' Danish operations will become the Roche Innovation Center
Shire extends rare genetic disease alliance

Agrees option with Santaris to nominate additional discovery targets. Shire has expanded its rare genetic disease alliance with Danish biopharmaceutical company Santaris. ... The Danish clinical stage biopharmaceutical company's president and CEO Henrik
RNA interference rebirth

ALN-RSV01. Alnylam. RSV. respiratory syncytial virus infection. IIb. miravirsen (SPC3649). Santaris Pharma. ... I. EZN-3042. Santaris Pharma. Survivin. cancer. I. EZN-2968. Santaris Pharma. HIF-1a.
Creative partnerships

In January, Pfizer extended an existing collaboration with Santaris ($614m) for the 'locked nucleic acid' (LNA) technology for gene-silencing RNA technology. ... Preclinical. 632. Santaris Pharma/Pfizer. Expansion of Locked Nucleic Acid Drug platform

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch table for August 2014

587.5. Santaris/ Roche (pRED). Company acquisition. Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics.
Pharma deals during August 2014

August also saw Roche's pRED group acquire Santaris Pharma for $450m - $250m upfront and $200m contingent on predetermined research milestones. ... Clearly it has not taken Roche long to be convinced of these claims given its $10m discovery alliance with
Deal Watch table for January 2014

Santaris/Roche. Discovery and development. Novel RNA targeted medicines using Santaris' locked nucleic acid drug platform.
Pharma deals during April 2013

Platform technologies. Of the 11 large pharma deals announced in April, 8 involve platform technologies. In addition to those already mentioned are: Ambrx / Astellas; Isis/ Roche; Ra/ Merck; Santaris/ Bristol-Myers ... Santaris/ BMS. April also saw
Deal Watch table for April 2013

199. Velcera/ Perrigo Company. Acquisition. Pet health products. 160. Santaris Pharma/ BMS.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Hansa Medical poaches Vifor Pharma’s CEO

Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in several senior commercial roles within Merck &Co and Sandoz Pharma.
Shire elects new chair

the recent purchase of Virophama and an alliance agreed last year with Santaris.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...